Analyst firms · Guggenheim · NMRA
Guggenheim NMRA price target and rating history
Neumora Therapeutics Inc. (NMRA) · Health Care
Guggenheim rates Neumora Therapeutics Inc. (NMRA) Buy with a $14 price target, as of its latest action on Oct 27, 2025. It has published 3 rating actions on NMRA since October 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a NMRA price target in the last 12 months, the median target is $7.
- Current rating
- Buy
- Price target
- $14
- Median target, all firms
- $7
- Actions on NMRA
- 3
Guggenheim price target on NMRA
Every Guggenheim rating on NMRA
- Oct 27, 2025
- Mar 7, 2025
- Oct 10, 2023
How other firms rate NMRA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $7 | Jun 16, 2026 |
| Needham | Buy | $5 | Jun 16, 2026 |
| William Blair | Outperform | Feb 17, 2026 | |
| Leerink Partners | Outperform | $8 | Jan 12, 2026 |
| RBC Capital Markets | Outperform | $7 | Dec 1, 2025 |
Questions about Guggenheim and NMRA
- What is Guggenheim's price target for NMRA?
- Guggenheim's latest stated price target for Neumora Therapeutics Inc. (NMRA) is $14, from its action on Oct 27, 2025.
- What is Guggenheim's rating on NMRA?
- Guggenheim rates NMRA Buy, a bullish rating, as of Oct 27, 2025.
- When did Guggenheim last change its view on NMRA?
- On Oct 27, 2025, Guggenheim upgrades to Buy from Neutral, price target $14.
- How does Guggenheim's NMRA target compare with other analysts?
- Across 4 firms with a NMRA price target in the last 12 months, the median target is $7.
More NMRA rating histories
All Guggenheim ratingsNMRA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.